Afatinib

Generic Name
Afatinib
Brand Names
Gilotrif, Giotrif
Drug Type
Small Molecule
Chemical Formula
C24H25ClFN5O3
CAS Number
850140-72-6
Unique Ingredient Identifier
41UD74L59M
Background

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...

Indication

Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...

Associated Conditions
Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
Associated Therapies
-
Clinical Trials
Related News

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

First Posted Date
2021-03-12
Last Posted Date
2023-10-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
857
Registration Number
NCT04795245
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

First Posted Date
2021-02-11
Last Posted Date
2022-01-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
110
Registration Number
NCT04750824
Locations
🇺🇸

Cardinal Health, Dublin, Ohio, United States

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

First Posted Date
2020-11-23
Last Posted Date
2020-12-23
Lead Sponsor
Hellenic Cooperative Oncology Group
Target Recruit Count
59
Registration Number
NCT04640870

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

First Posted Date
2020-10-05
Last Posted Date
2020-10-20
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
272
Registration Number
NCT04575415
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Phase 2
Conditions
Squamous Cell Carcinoma
Interventions
Drug: Afatinib
First Posted Date
2020-08-31
Last Posted Date
2020-08-31
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
20
Registration Number
NCT04533321
Locations
🇸🇬

National University Hospital, Singapore, Singapore

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Phase 4
Active, not recruiting
Conditions
Non-squamous NSCLC
Interventions
Drug: Osimertinib
Drug: Afatinib
First Posted Date
2020-06-02
Last Posted Date
2023-06-02
Lead Sponsor
Michael Hopp
Target Recruit Count
34
Registration Number
NCT04413201
Locations
🇩🇪

Sana-Klinikum Offenbach, Offenbach, Hessen, Germany

🇩🇪

Klinikum Bremen-Ost, Bremen, Germany

🇩🇪

Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh, Konstanz, Germany

and more 8 locations

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

First Posted Date
2019-12-20
Last Posted Date
2024-11-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
72
Registration Number
NCT04206787
Locations
🇨🇳

West China Hospital, Chengdu, China

🇨🇳

Hainan Cancer Hospital, Haikou, China

🇨🇳

First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 7 locations

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

First Posted Date
2019-12-17
Last Posted Date
2022-12-23
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
47
Registration Number
NCT04201756
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shang'ai, Shanghai, China

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

First Posted Date
2019-12-04
Last Posted Date
2024-11-28
Lead Sponsor
Amgen
Target Recruit Count
1200
Registration Number
NCT04185883
Locations
🇺🇸

Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States

🇺🇸

Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 87 locations

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

First Posted Date
2019-12-03
Last Posted Date
2024-10-16
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
102
Registration Number
NCT04183712
Locations
🇨🇳

Renji hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

🇨🇳

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy